ライフサイエンスコーパス: corneal disease

1 Heterozygotes have no corneal disease.

2 n tear fluid derived from virally associated corneal disease.

3 loss of neurotrophic support contributes to corneal disease.

4 growth of fungal hyphae and the severity of corneal disease.

5 F. solani keratitis, a potentially blinding corneal disease.

6 located posterior chamber IOL in 1 case with corneal disease.

7 lenses of patients with contact lens-related corneal disease.

8 successful cataract surgery in patients with corneal disease.

9 be used with caution in patients with prior corneal disease.

10 ulation, followed by cataract, glaucoma, and corneal disease.

11 d exciting possibilities in the treatment of corneal disease.

12 nal ganglia were inversely proportional with corneal disease.

13 nd underappreciated role in the treatment of corneal disease.

14 creasing number and variety of patients with corneal disease.

15 rneal development and to study the causes of corneal disease.

16 increased amounts of MIP133 and more severe corneal disease.

17 stimulates MIP133 secretion, and exacerbates corneal disease.

18 and its absence in MMP-9(-/-) mice decreased corneal disease.

19 in a significantly reduced capacity to cause corneal disease.

20 m or more should be evaluated for potential corneal disease.

21 ctions in triggering immune complex-mediated corneal disease.

22 IL-1beta polyclonal Ab significantly reduced corneal disease.

23 eal PMN number and significantly exacerbated corneal disease.

24 Both groups developed invasive corneal disease.

25 utic vaccine against recurrent HSV-1-induced corneal disease.

26 AS4 significantly decreased postreactivation corneal disease.

27 hod may also be applicable to other heredity corneal diseases.

28 and explains how two SNPs may contribute to corneal diseases.

29 rategy for the pathogenesis and treatment of corneal diseases.

30 itical defect tightly linked to common human corneal diseases.

31 mental models and therapeutic strategies for corneal diseases.

32 dry eye after refractive surgery, and other corneal diseases.

33 s a significant problem associated with many corneal diseases.

34 s, healthy subjects, and patients with other corneal diseases.

35 us, normal subjects, and patients with other corneal diseases.

36 Corneal disease 1 (Dstn(corn1)) mice are homozygous for

37 C57BL/6 mice showed significant corneal disease 1 and 3 days after infection, which was

38 Corneal disease-1 (corn1) and corn1(2J) are spontaneous

39 cal protection against primary HSV-1-induced corneal disease, a local ocular vaccine may prove more e

40 Lymphangiogenesis (LG) accompanies many corneal diseases after inflammatory, infectious, or chem

41 MIP-133 production is necessary to initiate corneal disease and plays an important role in the subse

42 LPS before challenge reduced the severity of corneal disease and protected challenged mice against pe

43 peutic topical application of CD ameliorated corneal disease and reduced the bacterial count in the e

44 vation are separable, (ii) the phenotypes of corneal disease and spontaneous reactivation are separab

45 33 production might be necessary to initiate corneal disease and that it may play an important role i

46 h as arthritis, inflammatory bowel diseases, corneal disease, and periodontitis.

47 Its efficacy against corneal disease appeared to be longer lasting than its e

48 and the use of popular current vital dyes in corneal disease are reviewed.

49 cal processes central to the pathogenesis of corneal disease, as well as other conditions including t

50 we found that two SNPs linked previously to corneal diseases, astigmatism, and Stevens-Johnson syndr

51 ce keratitis mimicking the onchocercal human corneal disease, BALB/c mice preimmunized with the bindi

52 function when visual impairment caused by a corneal disease becomes too severe.

53 motility contributed to the role of pili in corneal disease but was not involved in the role of pili

54 ease, compared with the production of severe corneal disease by 2 x 10(5) PFU of marker-rescued virus

55 Abrogation of virus-induced corneal disease by anti-cytokine antibodies suggests tha

56 Invasive corneal disease can be established with a surface inocul

57 PURPOSE OF REVIEW: Preexisting corneal disease can be exacerbated by cataract surgery a

58 (8) PFU per eye, d34.5 produced virtually no corneal disease, compared with the production of severe

59 were age- and sex-matched with no history of corneal disease (control group).

60 Inherited, iatrogenic, and metabolic corneal disease could be potentially treated by supplyin

61 d histopathologically, the human onchocercal corneal disease, demonstrating the antigenic specificity

62 t difference was that of more severe central corneal disease in DIF-negative patients.

63 This idiopathic spontaneous corneal disease in dogs shares clinical features with ch

64 or recurrent HSK as evidenced by the lack of corneal disease in mice treated with anti-CXCL1 Ab.

65 ins, and especially alpha-toxin, can mediate corneal disease in mice.

66 m solani and Fusarium oxysporum cause severe corneal disease in the United States and worldwide and w

67 Corneal disease in this strain was significantly reduced

68 eal physiology and in the pathophysiology of corneal disease, including modulation of keratocyte apop

69 g-h3) and furthermore that some of the human corneal disease-inducing substitutions identified in bet

70 red as a cost-effective treatment for severe corneal diseases internationally.

71 ever, delaying oral immunization until after corneal disease is established fails to mitigate keratit

72 Corneal disease is the most common cause of bilateral bl

73 Keratoconus(KC) is an ecstatic corneal disease leading to corneal-thinning and the form

74 as mock-immunized mice developed more severe corneal disease leading to stromal keratitis.

75 chs corneal dystrophy (FCD) is a progressive corneal disease marked by the development of guttae, foc

76 Mild ocular surface and corneal disease may be treated effectively with aggressi

77 Preexisting corneal disease must be managed appropriately to get the

78 h the changes observed in previously studied corneal diseases nor did they correlate with genes encod

79 ival, or it can promote diseases such as HSV corneal disease (or herpes stromal keratitis [HSK] in hu

80 important implications for the treatment of corneal disease, particularly corneal blindness due to L

81 n P. aeruginosa epithelial cell invasion and corneal disease pathogenesis was explored.

82 may be useful therapeutic targets in several corneal disease processes.

83 In vivo, corneal disease response grades in the heat-killed antig

84 ic neutralization of IL-2 after the onset of corneal disease resulted in a rapid regression of inflam

85 Treatment decreased corneal disease severity and reduced significantly the n

86 Corneal disease severity differed significantly among wi

87 d that extended to the cornea, such that HSV corneal disease severity was reduced in susceptible BALB

88 ct on the cornea also depends on preexisting corneal disease, severity and chronicity of intraocular

89 Signs of corneal disease should be identified preoperatively to a

90 efficacious against HSV-1-induced recurrent corneal disease than against recurrent HSV-1 ocular shed

91 ng elderly individuals; keratoconus (27%), a corneal disease that slowly deforms the cornea in young

92 ralization exacerbated P. aeruginosa-induced corneal disease, TIMP pAb- and normal rabbit serum (NRS)

93 val scarring (using Tauber staging), central corneal disease (vascularization, scarring, ulceration,

94 Corneal disease was categorized daily for 8 days with qu

95 Corneal disease was evaluated, and 7 to 378 days after i

96 entral nervous system (CNS) inflammation and corneal disease was evaluated, and responses in genetica

97 PAK strains in the cornea and development of corneal disease was impaired in DeltaexoS, DeltaexoT, an

98 a above 10(5) pfu the course and severity of corneal disease was not significantly different.

99 Corneal disease was quantified at regular intervals for

100 Recurrent HSV-1 corneal disease was significantly reduced by therapeutic

101 the homotypic gD1 vaccine against recurrent corneal disease, whereas the homotypic vaccine was much

102 role for endosymbiotic Wolbachia bacteria in corneal disease, which is characterized by neutrophil in

103 age-related macular degeneration, as well as corneal diseases with abnormal angiogenesis.

104 edicated towards the use of MSC for treating corneal diseases with very promising outcomes.